Skip to main content
Caplight Logo









Nilo Therapeutics

Nilo Therapeutics

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.nilotx.com/

Last Round

Series A

Oct 8, 2025

Total Funding Raised

$101M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Nilo Therapeutics is a biotechnology company that develops a class of medicines that harness neural circuits to restore immune homeostasis in disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyneuro-immunologydrug discoveryautoimmune diseasevagus nerveimmunomodulatorypreclinical researchbioelectronic medicineneural circuitsinflammatory diseasebiotech startuptherapeutic pipelinedrug licensingimmune homeostasisneuro-immune

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nilo Therapeutics Comparables

Compare Nilo Therapeutics with similar companies based on industry and business-model similarity.

Nilo Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GSK plc
74%
Kallyope
70%
Nimbus Therapeutics
67%

Nilo Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 8, 2025

Key People

Founding team and executive leadership

Kim Seth

President Chief Executive Officer

Executive Team

Nilo Therapeutics Investors

Notable investors and investment history

Nilo Therapeutics investors
InvestorRounds
The Column GroupSeries A
DCVC BioSeries A
Gates Family FoundationSeries A
Lux CapitalSeries A
Gates FoundationSeries A
Bill & Melinda Gates FoundationSeries A
Alexandria Venture InvestmentsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 8, 2025

    $101M Series A round completed.

  • Oct 8, 2025

    Kim Seth, Ph.D. appointed as Chief Executive Officer and Board director.

Nilo Therapeutics Filings

Explore SEC and related filing metadata, where available.

Nilo Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nilo Therapeutics's valuation, stock price, and market status.

Is Nilo Therapeutics a public or private company?

Nilo Therapeutics is a private company.

What is the current stock price of Nilo Therapeutics?

Nilo Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Nilo Therapeutics worth (valuation)?

Valuation information for Nilo Therapeutics is not publicly available.

Can I buy Nilo Therapeutics stock?

Nilo Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Nilo Therapeutics's last funding round?

Nilo Therapeutics's most recent funding round was Series A on October 8, 2025.

Who are the main investors in Nilo Therapeutics?

Key investors in Nilo Therapeutics include The Column Group, DCVC Bio, Lux Capital.

Will Nilo Therapeutics IPO soon?

No public IPO plans have been announced for Nilo Therapeutics.

How can I track Nilo Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nilo Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew York City, New York
Employee Range33
Year Founded2024
Last FundingOct 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?